Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care
NJ Talley, MG Moore, A Sprogis… - Medical journal of …, 2002 - Wiley Online Library
NJ Talley, MG Moore, A Sprogis, P Katelaris
Medical journal of Australia, 2002•Wiley Online LibraryObjectives: To investigate whether pantoprazole (20 mg/d) produces significantly greater
symptom control than ranitidine (300 mg/d) in patients with gastro‐oesophageal reflux
disease (GORD). Design: Multicentre, randomised, double‐blind, parallel‐group
comparison. Setting: 76 general practices in north‐west Sydney and Newcastle, New South
Wales (Australia), from 19 January 1999 to 22 September 2000. Patients: 307 patients aged
18 years or over presenting with symptomatic GORD. Interventions: Pantoprazole (20 mg …
symptom control than ranitidine (300 mg/d) in patients with gastro‐oesophageal reflux
disease (GORD). Design: Multicentre, randomised, double‐blind, parallel‐group
comparison. Setting: 76 general practices in north‐west Sydney and Newcastle, New South
Wales (Australia), from 19 January 1999 to 22 September 2000. Patients: 307 patients aged
18 years or over presenting with symptomatic GORD. Interventions: Pantoprazole (20 mg …
Abstract
Objectives: To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro‐oesophageal reflux disease (GORD).
Design: Multicentre, randomised, double‐blind, parallel‐group comparison.
Setting: 76 general practices in north‐west Sydney and Newcastle, New South Wales (Australia), from 19 January 1999 to 22 September 2000.
Patients: 307 patients aged 18 years or over presenting with symptomatic GORD.
Interventions: Pantoprazole (20 mg once daily) or ranitidine (150 mg twice daily).
Main outcome measures: Patient‐assessed frequency and severity of heartburn using the Gastrointestinal Symptom Rating Scale (GSRS) and a patient heartburn diary.
Results: Pantoprazole was associated with significantly higher rates of complete control of GORD symptoms than ranitidine at four weeks (40% v 19%; P < 0.001), eight weeks (55% v 33%; P < 0.001), six months (71% v 56%; P = 0.007) and 12 months (77% v 59%; P = 0.001).
Conclusions: Low‐dose pantoprazole is an effective alternative to standard‐dose ranitidine for initial and maintenance treatment of patients with symptomatic GORD.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果